Oxitec set to expand GM mosquito trials in Brazil

Screen Shot at AM

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

Oxitec and Piracicaba City Hall have finalized their multi-year expansion of the ‘Friendly Aedes aegypti Project’ to cover an area of 60,000 people in the center of the city of Piracicaba, Brazil.  Due to the large number of people who travel through this region, this project may also benefit neighbouring areas of the city.  Additionally, the initial project, which has been deploying Oxitec’s OX513A solution in an area of 5,000 people in the CECAP/Eldorado district since April 2015, has been extended.

“Piracicaba’s decision to broaden the reach of our project demonstrates their confidence in our innovative vector control solution and is an important step forward in the effort to combat the dangerous Aedes aegypti mosquito, and the viruses it transmits, in a highly targeted and environmentally safe manner,” said Oxitec Chief Executive Officer Hadyn Parry.

It is estimated that up to half of the world’s population lives alongside the dangerous Aedes aegypti mosquitoes which are the primary vector for dengue, chikungunya, and Zika virus — some of the most damaging arboviruses to public health and economies of nations.

Read full, original post: Oxitec Expands Vector Control Solution in Brazil

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot 2026-05-26 at 10.15
Viewpoint: Double standard—Why does the wellness industry get a free pass while Big Healthcare is treated as morally suspect?
ChatGPT-Image-Jun-4-2026-11_49_36-AM-2
‘You don’t understand Tolkien’: Skeptic Pope trolls tech giants about the exaggerated, risk-less benefits of AI
Screenshot-2026-06-04-at-12.05.08-PM
Cases of brain inflammation surge as U.S. measles pandemic approaches 2000
ChatGPT-Image-Jun-4-2026-01_27_58-PM
Viewpoint—N.A.D.+: Why Gwenyth Paltrow’s heralded anti-aging supplement doesn’t work
Screenshot 2025-07-30 at 10.48
Can gene editing eliminate Down syndrome? Scientists have done it in lab-grown cells
ChatGPT Image May 26, 2026, 08_42_17 AM (1)
Viewpoint: Greenpeace and poison: How environmental advocacy groups rely on compliant (and often ignorant) journalists to spread disinformation and spark litigation
Screenshot-2026-06-03-at-1.24.46-PM
Challenging anti-GMO disinformation: Why genetically-tweaked crops offer bushels of benefits
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
ChatGPT Image May 26, 2026, 08_21_36 AM
Limiting gender affirming interventions: Trump administration targets Texas even though it already bans youth access
tick-DNA
GLP podcast: Spread meat allergy with gene-edited ticks? Bioethicists pose vile ‘thought experiment’
Screenshot 2026-06-04 at 12.43
Viewpoint: Doctors who are battling Ebola are incredulous that U.S. government is not utilizing specially designed emergency health units meant to fight virulent disease
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.